Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis

Cell Cycle

Volumn 10, Issue 16, 2011, Pages 2792-2805

  Martínez Paniagua, Melisa A ^a,b,c   Baritaki, Stavroula ^c   Huerta Yepez, Sara ^c,d   Ortiz Navarrete, Vianney F ^e   González Bonilla, Cesar ^a   Bonavida, Benjamin ^c   Vega, Mario I ^c,f  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^e DEPARTAMENTO DE FÍSICA   (Mexico)

^f HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

DR5; Immunosensitization; Lymphoma; Obatoclax; TRAIL; YY1

Indexed keywords

BH3 PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OBATOCLAX; PROTEIN BAK; PROTEIN BCL 2; PROTEIN MCL 1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR YY1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG SENSITIZATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOMA CELL; MEDIATOR; NONHODGKIN LYMPHOMA; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

EID: 80051745794     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.16.16952     Document Type: Article

References (63)

1. Mimeault M., Batra S.K. New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histol Histopathol 2010; 25:1057-1073; PMID:20552555.
2. Sung E.S., Park K.J., Lee S.H., Jang Y.S., Park S.K., Park Y.H., et al. A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Mol Cancer Ther 2009; 8:2276-85; PMID:19638452; DOI:10.1158/1535-7163.MCT-09-0235.
3. Zinonos I., Labrinidis A., Lee M., Liapis V., Hay S., Ponomarev V., et al. Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Mol Cancer Ther 2009; 8:2969-80; PMID:19808976; DOI:10.1158/1535-7163.MCT-09-0745.
4. Wiezorek J., Holland P., Graves J Death receptor agonists as a targeted therapy for cancer Clin Cancer Res 2010; 16:1701-8; PMID:20197482; DOI:10.1158/1078-0432.CCR-09-1692.
5. Sheikh M.S., Fornace A.J. Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000; 14:1509-13; PMID:10942251; DOI:10.1038/sj.leu.2401865.
6. Reid P., Holen I Pathophysiological roles of osteoprotegerin (OPG) Eur J Cell Biol 2009; 88:1-17; PMID:18707795; DOI:10.1016/j.ejcb.2008.06.004.
7. Kruyt FA TRAIL and cancer therapy Cancer Lett 2008; 263:14-25; PMID:18329793; DOI:10.1016/j.canlet.2008.02.003.
8. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family J Biol Chem 1996; 271:12687-90; PMID:8663110; DOI:10.1074/jbc.271.22.12687.
9. Camidge D.R., Herbst R.S., Gordon M.S., Eckhardt S.G., Kurzrock R., Durbin B., et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010; 16:1256-63; PMID:20145186; DOI:10.1158/1078-0432.CCR-09- 1267.
10. Trarbach T., Moehler M., Heinemann V., Kohne C.H., Przyborek M., Schulz C., et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010; 102:506-12; PMID:20068564; DOI:10.1038/sj.bjc.6605507.
11. Testa U. TRAIL/TRAIL-R in hematologic malignancies. J Cell Biochem 2010; 110:21-34; PMID:20336667.
12. Mahalingam D., Szegezdi E., Keane M de JS, Samali A TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009; 35:280-8; PMID:19117685; DOI:10.1016/j.ctrv.2008.11.006.
13. Zhang L., Fang B Mechanisms of resistance to TRAILinduced apoptosis in cancer Cancer Gene Ther 2005; 12:228-37; PMID:15550937; DOI:10.1038/sj.cgt. 7700792.
14. Vogler M., Dinsdale D., Dyer M.J., Cohen GM Bcl-2 inhibitors: small molecules with a big impact on cancer therapy Cell Death Differ 2009; 16:360-7; PMID:18806758; DOI:10.1038/cdd.2008.137.
15. Ray S., Bucur O., Almasan A Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor Apoptosis 2005; 10:1411-8; PMID:16215673; DOI:10.1007/s10495-005-2490-y.
16. Kang M.H., Reynolds CP Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin Cancer Res 2009; 15:1126-32; PMID:19228717; DOI:10.1158/1078-0432.CCR-08-0144.
17. Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy M., et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104:19512-7; PMID:18040043; DOI:10.1073/pnas.0709443104.
18. Huang S., Okumura K., Sinicrope FA BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells Clin Cancer Res 2009; 15:150-9; PMID:19118042; DOI:10.1158/1078-0432.CCR-08-1575.
19. Mott J.L., Bronk S.F., Mesa R.A., Kaufmann S.H., Gores GJ BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis Mol Cancer Ther 2008; 7:2339-47; PMID:18723481; DOI:10.1158/1535-7163.MCT-08-0285.
20. Smoot R.L., Blechacz B.R., Werneburg N.W., Bronk S.F., Sinicrope F.A., Sirica A.E., et al. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res 2010; 70:1960-9; PMID:20160031; DOI:10.1158/0008-5472.CAN-09-3535.
21. Jiang C.C., Wroblewski D., Yang F., Hersey P., Zhang X.D. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Neoplasia 2009; 11:945-955; PMID:19724688.
22. Konopleva M., Watt J., Contractor R., Tsao T., Harris D., Estrov Z., et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008; 68:3413-20; PMID:18451169; DOI:10.1158/0008-5472.CAN-07-1919.
23. Li J., Viallet J., Haura EB A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells Cancer Chemother Pharmacol 2008; 61:525-34; PMID:17505826; DOI:10.1007/s00280-007-0499-3.
24. Pérez-Galán P., Roue G., Villamor N., Campo E., Colomer D The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak Blood 2007; 109:4441-9; PMID:17227835; DOI:10.1182/blood- 2006-07-034173.
25. Dixit V., Mak TW NFkappaB signaling Many roads lead to madrid Cell 2002; 111:615-9; PMID:12464174; DOI:10.1016/S0092-8674(02)01166-2.
26. Gasparian A.V., Yao Y.J., Kowalczyk D., Lyakh L.A., Karseladze A., Slaga T.J., et al. The role of IKK in constitutive activation of NFkappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002; 115:141-151; PMID:11801732.
27. Ghosh S., Karin M Missing pieces in the NFkappaB puzzle Cell 2002; 109:81-96; PMID:11983155; DOI:10.1016/S0092-8674(02)00703-1.
28. Lee H.H., Dadgostar H., Cheng Q., Shu J., Cheng G NFkappaB-mediated upregulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes Proc Natl Acad Sci USA 1999; 96:9136-41; PMID:10430908; DOI:10.1073/pnas.96.16.9136.
29. Jazirehi A.R., Vega M.I., Bonavida B Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy Cancer Res 2007; 67:1270-81; PMID:17283164; DOI:10.1158/0008-5472.CAN-06-2184.
30. Kimura N., Miyakawa Y., Kohmura K., Umezawa K., Ikeda Y., Kizaki M Targeting NFkappaB and induction of apoptosis by novel NFkappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells Leuk Res 2007; 31:1529-35; PMID:17466373; DOI:10.1016/j.leukres.2007.02.015.
31. Vega M.I., Martinez-Paniagua M., Jazirehi A.R., Huerta-Yepez S., Umezawa K., Martinez-Maza O., et al. The NFkappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma 2008; 49:1982-94; PMID:18949621; DOI:10.1080/10428190802357071.
32. Watanabe M., Ohsugi T., Shoda M., Ishida T., Aizawa S., Maruyama-Nagai M., et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NFkappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 2005; 106:2462-71; PMID:15956280; DOI:10.1182/blood-2004-09-3646.
33. Brem E.A., Thudium K., Khubchandani S., Tsai P.C., Olejniczak S.H., Bhat S., et al. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol 2011; 153:599-611; PMID:21492126; DOI:10.1111/j.1365-2141.2011.08669.x.
34. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., Korsmeyer SJ Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics Cancer Cell 2002; 2:183-92; PMID:12242151; DOI:10.1016/S1535-6108(02)00127-7.
35. Pérez-Galán P., Roue G., Lopez-Guerra M., Nguyen M., Villamor N., Montserrat E., et al. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15- 070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 2008; 22:1712-20; PMID:18596739; DOI:10.1038/leu.2008.175.
36. Trudel S., Li Z.H., Rauw J., Tiedemann R.E., Wen X.Y., Stewart AK Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma Blood 2007; 109:5430-8; PMID:17332241; DOI:10.1182/blood-2006-10-047951.
37. Huerta-Yepez S., Vega M., Escoto-Chavez S.E., Murdock B., Sakai T., Baritaki S., et al. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide 2009; 20:39-52; PMID:18778787; DOI:10.1016/j.niox.2008.08.001.
38. Baritaki S., Katsman A., Chatterjee D., Yeung K.C., Spandidos D.A., Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 upregulation. J Immunol 2007; 179:5441-5453; PMID:17911631.
39. Baritaki S., Huerta-Yepez S., Sakai T., Spandidos D.A., Bonavida B Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: upregulation of DR5 and inhibition of Yin Yang 1 Mol Cancer Ther 2007; 6:1387-99; PMID:17431117; DOI:10.1158/1535-7163.MCT-06-0521.
40. Baritaki S., Suzuki E., Umezawa K., Spandidos D.A., Berenson J., Daniels T.R., et al. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol 2008; 180:6199-6210; PMID:18424742.
41. Vega M.I., Baritaki S., Huerta-Yepez S, Martinez- Paniagua MA, Bonavida B A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells Leuk Lymphoma 2011; 52:108-21; PMID:21133714; DOI:10.3109/10428194.2010.531408.
42. Deng X., Gao F., Flagg T., Anderson J., May WS Bcl2's flexible loop domain regulates p53 binding and survival Mol Cell Biol 2006; 26:4421-34; PMID:16738310; DOI:10.1128/MCB.01647-05.
43. Graupner V., Alexander E., Overkamp T., Rothfuss O., De Laurenzi V., Gillissen B.F., et al. Differential regulation of the proapoptotic multidomain protein Bak by p53 and p73 at the promoter level. Cell Death Differ 2011; 18:1130-9; PMID:21233848; DOI:10.1038/cdd.2010.179.
44. Massaad C.A., Portier B.P., Taglialatela G Inhibition of transcription factor activity by nuclear compartmentassociated Bcl-2 J Biol Chem 2004; 279:54470-8; PMID:15471874; DOI:10.1074/jbc.M407659200.
45. Grimm S., Bauer M.K., Baeuerle P.A., Schulze-Osthoff K Bcl-2 downregulates the activity of transcription factor NFkappaB induced upon apoptosis J Cell Biol 1996; 134:13-23; PMID:8698809; DOI:10.1083/jcb.134.1.13.
46. Hour T.C., Chen L., Lin JK Suppression of transcription factor NFkappaB activity by Bcl-2 protein in NIH3T3 cells: implication of a novel NFkappaB p50-Bcl-2 complex for the anti-apoptotic function of Bcl-2 Eur J Cell Biol 2000; 79:121-9; PMID:10727020; DOI:10.1078/S0171-9335(04)70014-X.
47. Kuwana T., Bouchier-Hayes L., Chipuk J.E., Bonzon C., Sullivan B.A., Green D.R., et al. BH3 domains of BH3-only proteins differentially regulate Baxmediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17:525-35; PMID:15721256; DOI:10.1016/j.molcel.2005. 02.003.
48. Jiang P., Du W., Heese K., Wu M The Bad guy cooperates with good cop p53: Bad is transcriptionally upregulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis Mol Cell Biol 2006; 26:9071-82; PMID:17000778; DOI:10.1128/MCB.01025-06.
49. Sax J.K., Fei P., Murphy M.E., Bernhard E., Korsmeyer S.J., El-Deiry WS BID regulation by p53 contributes to chemosensitivity Nat Cell Biol 2002; 4:842-9; PMID:12402042; DOI:10.1038/ncb866.
50. Glasgow J.N., Qiu J., Rassin D., Grafe M., Wood T., Perez-Pol JR Transcriptional regulation of the BCL-X gene by NFkappaB is an element of hypoxic responses in the rat brain Neurochem Res 2001; 26:647-59; PMID:11519724; DOI:10.1023/A:1010987220034.
51. Petlickovski A., Laurenti L., Li X., Marietti S., Chiusolo P., Sica S., et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005; 105:4820-7; PMID:15728130; DOI:10.1182/blood-2004-07-2669.
52. Stehlik C de MR, Binder BR, Lipp J Cytokine induced expression of porcine inhibitor of apoptosis protein (iap) family member is regulated by NFkappaB Biochem Biophys Res Commun 1998; 243:827-32; PMID:9501011; DOI:10.1006/bbrc. 1998.8185.
53. Wu M., Lee H., Bellas R.E., Schauer S.L., Arsura M., Katz D., et al. Inhibition of NFkappaB/Rel induces apoptosis of murine B cells. EMBO J 1996; 15:4682-4690; PMID:8887559.
54. Fulda S., Galluzzi L., Kroemer G Targeting mitochondria for cancer therapy Nat Rev Drug Discov 2010; 9:447-64; PMID:20467424; DOI:10.1038/nrd3137.
55. Akgul C Mcl-1 is a potential therapeutic target in multiple types of cancer Cell Mol Life Sci 2009; 66:1326-36; PMID:19099185; DOI:10.1007/s00018- 008-8637-6.
56. Feng C.Y., Rise ML Characterization and expression analyses of anti-apoptotic Bcl-2-like genes NR-13, Mcl- 1, Bcl-X1 and Bcl-X2 in Atlantic cod (Gadus morhua) Mol Immunol 2010; 47:763-84; PMID:19923001; DOI:10.1016/j. molimm.2009.10.011.
57. Paik P.K., Rudin C.M., Pietanza M.C., Brown A., Rizvi N.A., Takebe N. et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 2011; PMID: 21620511; DOI:10.1016/j.lungcan.2011.05.005.
58. Paik P.K., Rudin C.M., Brown A., Rizvi N.A., Takebe N., Travis W., et al. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 2010; 66:1079-85; PMID:20165849; DOI:10.1007/s00280-010-1265-5.
59. Vega M.I., Huerta-Yepez S., Martinez-Paniagua M., Martinez-Miguel B., Hernandez-Pando R, Gonzalez- Bonilla CR, et al Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions Clin Cancer Res 2009; 15:6582-94; PMID:19861448; DOI:10.1158/1078- 0432.CCR-09-1234.
60. Huerta-Yepez S., Vega M., Garban H., Bonavida B Involvement of the TNFalpha autocrine-paracrine loop, via NFkappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis Clin Immunol 2006; 120:297-309; PMID:16784892; DOI:10.1016/j.clim.2006.03.015.
61. Umezawa K., Chaicharoenpong C. Molecular design and biological activities of NFkappaB inhibitors. Mol Cells 2002; 14:163-167; PMID:12442886.
62. Vega M.I., Huerta-Yepaz S., Garban H., Jazirehi A., Emmanouilides C., Bonavida B Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance Oncogene 2004; 23:3530-40; PMID:15077178; DOI:10.1038/sj.onc.1207336.
63. Berenbaum MC A method for testing for synergy with any number of agents J Infect Dis 1978; 137:122-30; PMID:627734; DOI:10.1093/infdis/137.2.122.